ZA943895B - Substituted benzoylguanidines process for their preparation their use as a medicament or diagnostic and medicament containing them - Google Patents

Substituted benzoylguanidines process for their preparation their use as a medicament or diagnostic and medicament containing them

Info

Publication number
ZA943895B
ZA943895B ZA943895A ZA943895A ZA943895B ZA 943895 B ZA943895 B ZA 943895B ZA 943895 A ZA943895 A ZA 943895A ZA 943895 A ZA943895 A ZA 943895A ZA 943895 B ZA943895 B ZA 943895B
Authority
ZA
South Africa
Prior art keywords
perfluoro
cycloalkyl
phenyl
alkyl
biphenylyl
Prior art date
Application number
ZA943895A
Other languages
English (en)
Inventor
Jan-Robert Schwark
Heinz-Werner Kleemann
Hans-Jochen Lang
Andreas Wiechert
Wolfgang Scholtz
Udo Albus
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of ZA943895B publication Critical patent/ZA943895B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/22—Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
ZA943895A 1993-06-05 1994-06-03 Substituted benzoylguanidines process for their preparation their use as a medicament or diagnostic and medicament containing them ZA943895B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4318756A DE4318756A1 (de) 1993-06-05 1993-06-05 Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US08/459,966 US5679712A (en) 1993-06-05 1995-06-02 Substituted benzoylguanidines, process for their preparation, their use as a pharmaceutical or diagnostic, and pharmaceutical containing them

Publications (1)

Publication Number Publication Date
ZA943895B true ZA943895B (en) 1995-02-21

Family

ID=25926534

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA943895A ZA943895B (en) 1993-06-05 1994-06-03 Substituted benzoylguanidines process for their preparation their use as a medicament or diagnostic and medicament containing them

Country Status (17)

Country Link
US (2) US5679712A (fi)
EP (1) EP0628543B1 (fi)
JP (1) JP3563106B2 (fi)
CN (1) CN1068308C (fi)
AT (1) ATE181322T1 (fi)
AU (1) AU674744B2 (fi)
CA (1) CA2125104C (fi)
DE (2) DE4318756A1 (fi)
DK (1) DK0628543T3 (fi)
ES (1) ES2134878T3 (fi)
FI (1) FI942599A (fi)
GR (1) GR3031111T3 (fi)
HU (1) HU219452B (fi)
IL (1) IL109887A (fi)
NO (1) NO302361B1 (fi)
NZ (1) NZ260681A (fi)
ZA (1) ZA943895B (fi)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0612723B1 (de) * 1993-02-20 1997-08-27 Hoechst Aktiengesellschaft Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, als Inhibitoren des zellulären Na+/H+-Austauschs oder als Diagnostikum sowie sie enthaltendes Medikament
IL109570A0 (en) * 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
DE4318658A1 (de) * 1993-06-04 1994-12-08 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4318756A1 (de) * 1993-06-05 1994-12-08 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4421536A1 (de) * 1994-06-20 1995-12-21 Hoechst Ag Perfluoralkylgruppen tragende phenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
IL114670A0 (en) * 1994-08-05 1995-11-27 Fujisawa Pharmaceutical Co Guanidine derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
DE4430213A1 (de) * 1994-08-28 1996-02-29 Merck Patent Gmbh Arylbenzoylguanidine
DE4441880A1 (de) * 1994-11-24 1996-05-30 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19502895A1 (de) * 1995-01-31 1996-08-01 Merck Patent Gmbh 4-Mercapto-benzoylguanidin-Derivate
DE19517848A1 (de) * 1995-05-16 1996-11-21 Merck Patent Gmbh Fluorhaltige Benzoylguanidine
DE19531138A1 (de) * 1995-08-24 1997-02-27 Merck Patent Gmbh Alkenyl-benzoylguanidin-Derivate
EP0765868A1 (de) * 1995-09-27 1997-04-02 Hoechst Aktiengesellschaft Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Antiarhythmika oder als Diagnostikum sowie sie enthaltendes Medikament
EP0765867A1 (de) * 1995-09-27 1997-04-02 Hoechst Aktiengesellschaft Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Antiarrhytmika oder Diagnostikum sowie sie enthaltendes Medikament
DE19540995A1 (de) * 1995-11-03 1997-05-07 Hoechst Ag Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19542306A1 (de) * 1995-11-14 1997-05-15 Hoechst Ag Sulfonylamino-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
PL316439A1 (en) * 1995-11-20 1997-05-26 Hoechst Ag Novel substituted derivatives of benzoyloguanidine, method of obtaining them, their application in production of pharmaceutic and diagnostic agents and pharmaceutic agent as such
DE19546736A1 (de) * 1995-12-14 1997-06-19 Hoechst Ag Substituierte Chromanylsulfonyl(thio)harnstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Präparate
CA2195697A1 (en) 1996-02-02 1997-08-03 Masahumi Kitano Novel substituted guanidine derivatives, process for production thereof, and pharmaceutical uses thereof
DE19608162A1 (de) * 1996-03-04 1997-09-11 Hoechst Ag Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19608161A1 (de) 1996-03-04 1997-09-11 Hoechst Ag Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19621319A1 (de) * 1996-05-28 1997-12-04 Hoechst Ag Bis-ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19622370A1 (de) * 1996-06-04 1997-12-11 Hoechst Ag Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19624178A1 (de) * 1996-06-18 1998-01-08 Hoechst Ag Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19737463A1 (de) * 1997-08-28 1999-03-04 Hoechst Marion Roussel De Gmbh Verwendung von Inhibitoren des Natrium-Wasserstoff-Austauschers zur Herstellung eines Arzneimittels zur Behandlung von Erkrankungen, die durch Protozoen verursacht werden
IL126276A0 (en) * 1997-09-24 1999-05-09 Hoechst Marion Roussel De Gmbh The use of an inhibitor of the na+/H+ exchanger for the production of a medicament for the treatment or prophylaxis of disorders of the central nervous system
US6410563B1 (en) 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
US6639077B2 (en) 2000-03-23 2003-10-28 Merck Frosst Canada & Co. Tri-aryl-substituted-ethane PDE4 inhibitors
MY123585A (en) 2000-03-23 2006-05-31 Merck Canada Inc Tri-aryl-substituted-ethane pde4 inhibitors.
AU6196201A (en) 2000-05-25 2001-12-03 Merck Frosst Canada Inc Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
US6740666B2 (en) 2000-12-20 2004-05-25 Merck & Co., Inc. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
EP1397359B1 (en) 2001-05-24 2005-08-31 Merck Frosst Canada & Co. 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors
JO2311B1 (en) 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
ATE486600T1 (de) 2002-03-12 2010-11-15 Merck Sharp & Dohme Di-aryl-substituierte tetrazol-modulatoren des metabotropen glutamat-rezeptors-5
US20060148700A1 (en) * 2004-11-10 2006-07-06 Daria Mochly-Rosen Methods and compositions for reducing injury to a transplanted organ
US8399460B2 (en) 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
US8530470B2 (en) 2011-04-13 2013-09-10 Astrazeneca Ab Chromenone derivatives
US10344002B2 (en) 2016-09-26 2019-07-09 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1939738A1 (de) * 1969-08-05 1971-02-18 Boehringer Mannheim Gmbh Aminoguanidine und Verfahren zur Herstellung derselben
US3780027A (en) * 1970-04-29 1973-12-18 Merck & Co Inc Anthranilic acid derivatives
DE2935062A1 (de) * 1978-09-06 1980-03-20 Degussa Substituierte aminoalkylguanidine, deren herstellung und arzneimittel
DE3929582A1 (de) * 1989-09-06 1991-03-07 Hoechst Ag Benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltendes medikament
CZ284456B6 (cs) * 1992-02-15 1998-12-16 Hoechst Aktiengesellschaft Aminosubstituované benzoylguanidiny, způsob jejich přípravy, jejich použití jako léčiv a léčivo, které je obsahuje
EP0556674B1 (de) * 1992-02-15 1996-06-19 Hoechst Aktiengesellschaft 3,5-Substituierte Benzoylguanidine, mit antiarrythmischer Wirkung und inhibierender Wirkung auf die Proliferationen von Zellen
ATE158278T1 (de) * 1992-02-15 1997-10-15 Hoechst Ag Ortho-substituierte benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament oder diagnostikum sowie sie enthaltendes medikament
EP0612723B1 (de) * 1993-02-20 1997-08-27 Hoechst Aktiengesellschaft Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, als Inhibitoren des zellulären Na+/H+-Austauschs oder als Diagnostikum sowie sie enthaltendes Medikament
DE4318658A1 (de) * 1993-06-04 1994-12-08 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4318756A1 (de) * 1993-06-05 1994-12-08 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Also Published As

Publication number Publication date
US5679712A (en) 1997-10-21
US5849775A (en) 1998-12-15
NZ260681A (en) 1996-02-27
JP3563106B2 (ja) 2004-09-08
IL109887A (en) 1998-02-22
HU9401431D0 (en) 1994-08-29
FI942599A0 (fi) 1994-06-02
HU219452B (hu) 2001-04-28
AU6454494A (en) 1994-12-08
NO942063D0 (no) 1994-06-03
DK0628543T3 (da) 1999-11-22
JPH06345715A (ja) 1994-12-20
EP0628543A1 (de) 1994-12-14
DE59408409D1 (de) 1999-07-22
CA2125104C (en) 2006-03-28
ES2134878T3 (es) 1999-10-16
AU674744B2 (en) 1997-01-09
EP0628543B1 (de) 1999-06-16
NO942063L (no) 1994-12-06
DE4318756A1 (de) 1994-12-08
CA2125104A1 (en) 1994-12-06
CN1097737A (zh) 1995-01-25
IL109887A0 (en) 1994-10-07
HUT70554A (en) 1995-10-30
CN1068308C (zh) 2001-07-11
NO302361B1 (no) 1998-02-23
FI942599A (fi) 1994-12-06
ATE181322T1 (de) 1999-07-15
GR3031111T3 (en) 1999-12-31

Similar Documents

Publication Publication Date Title
ZA943895B (en) Substituted benzoylguanidines process for their preparation their use as a medicament or diagnostic and medicament containing them
DE59408722D1 (de) Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GR3025798T3 (en) Substituted benzoylguanidines, process for their preparation, their use as medicine or in diagnostic and medicines containing them.
DE59302745D1 (de) Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Antiarrhythmika
CA2111512A1 (en) 3,5-substituted aminobenzoylguanidines, process for their preparation, their use as a medicament or diagnostic and medicament containing them
DE59405764D1 (de) Harnstoffsubstituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament